Retatrutide — Triple Agonist GLP-1/GIP/Glucagon
Triple agonist of GLP-1 + GIP + glucagon — investigational Phase 3 molecule (Eli Lilly). Up to -24% body weight over 48 weeks in Phase 2 trial. Not approved by FDA/EMA.
Phase 2, 48 weeks (NEJM 2023)
What is Retatrutide?
LY3437943 · Phase 3
Retatrutide (LY3437943) is a triple receptor agonist targeting GLP-1, GIP and glucagon receptors. It is the first product to simultaneously activate three key signaling pathways for weight regulation.
Unlike Ozempic (semaglutide, single receptor — GLP-1) or Mounjaro (tirzepatide, dual receptor — GLP-1 + GIP), Retatrutide adds a third component — the glucagon receptor, which increases energy expenditure and thermogenesis.
Phase 2 trial results (NEJM, 2023) confirmed record efficacy — up to 24.2% weight loss over 48 weeks, surpassing all existing products.
🔬 Key advantage: Retatrutide is the only triple agonist. Three receptors simultaneously = appetite suppression (GLP-1) + fat metabolism (GIP) + increased thermogenesis (glucagon).
How Retatrutide Works
Triple action on three receptors simultaneously — GLP-1, GIP and glucagon — delivers the highest efficacy among all weight management products.
You inject once a week (thin needle, subcutaneous — painless)
Three receptors receive the signal simultaneously: appetite decreases, fat metabolism activates, energy expenditure increases
In Phase 2 trials, participants lost an average of up to −24.2% body weight over 48 weeks — combined with healthy eating and specialist support (Retatrutide — investigational, not FDA/EMA approved)
GLP-1: Appetite Suppression
Acts on hunger centers in the hypothalamus, reducing appetite and food cravings. Slows gastric emptying for prolonged satiety. The primary mechanism of Ozempic.
GIP: Fat Metabolism
Enhances fat tissue burning and improves insulin sensitivity. This receptor is present in Mounjaro but absent in Ozempic — making the dual agonist more effective.
Glucagon: Energy Expenditure
The unique third component of Retatrutide. Increases thermogenesis and basal metabolism — the body burns more calories even at rest. Absent in Mounjaro and Ozempic.
Retatrutide acts simultaneously on three receptors: GLP-1 suppresses appetite, GIP improves fat metabolism, and glucagon boosts thermogenesis. The triple mechanism delivers up to −24.2% weight loss over 48 weeks (Phase 2, NEJM 2023) — significantly more than dual (Mounjaro) or mono-agonists (Ozempic).
Triple Advantage of Retatrutide
Ozempic acts through 1 receptor (GLP-1). Mounjaro — through 2 receptors (GLP-1 + GIP). Retatrutide adds a third — the glucagon receptor, which triggers thermogenesis and increases basal metabolism.
The third component is a revolution: the body burns more calories even at rest. This is precisely why Retatrutide showed the highest efficacy among all GLP-1 agonists in clinical trials.
Which product is right for you?
Retatrutide, Mounjaro or Ozempic? Take the 8-step survey — and get a personalized recommendation.
Start the quiz →
Which product
is right for you?
Retatrutide, Mounjaro or Ozempic? Take the 8-step survey — and get a personalized recommendation.
No obligations. Results immediately after completion.
Who is Retatrutide For
✓Recommended
- ✓BMI ≥ 27 with a desire to lose weight
- ✓Insufficient effect from single/dual agonists
- ✓Desire for maximum efficacy
- ✓Metabolic syndrome or insulin resistance
- ✓Readiness for a long-term program
✕Not Recommended
- ✕Pregnancy and breastfeeding
- ✕Age under 18
- ✕Medullary thyroid carcinoma (MEN2)
- ✕Acute pancreatitis
- ✕Allergy to components
Not sure? Ask a DOZA specialist — free consultation.
Retatrutide Clinical Trial Results
Phase 2 (NEJM, 2023)
In the Phase 2 trial (New England Journal of Medicine, 2023), 338 adults with obesity received Retatrutide at various doses over 48 weeks. At the highest dose (12 mg), the mean weight loss was 24.2% of initial body weight — a record result among all GLP-1 products.
For comparison: Mounjaro (tirzepatide) showed -22.5% over 72 weeks, and Ozempic (semaglutide) — -15% over 68 weeks. Retatrutide achieved a better result in less time.
Results by Dose
- • 1 mg: -8.7% weight over 48 weeks
- • 4 mg: -17.1% weight over 48 weeks
- • 8 mg: -22.8% weight over 48 weeks
- • 12 mg: -24.2% weight over 48 weeks
Key Phase 2 Findings
- • 100% of participants on 12 mg lost ≥5% weight
- • 93% of participants — ≥10% weight
- • 83% of participants — ≥15% weight
- • Third receptor (glucagon) increased the effect by ~10%
Retatrutide Dosing
The dose is increased gradually (escalation) to minimize adaptation symptoms. Standard target dose is 4 mg, with the option to increase at the specialist's discretion.
Minimum starting dose for body adaptation. Mild appetite reduction.
Primary target dose. Active weight loss, appetite and metabolism control.
Increased dose for more pronounced results at the specialist's discretion.
Highest dose from Phase 2 trials. Maximum efficacy — up to -24% weight loss.
Retatrutide Adaptation Features
Adaptation symptoms are similar to other GLP-1 agonists. Gradual dose escalation minimizes discomfort.
A DOZA specialist supports the entire adaptation process and helps minimize any discomfort. Consultation — via Telegram.
Choose Your Retatrutide
Individual dose or pre-filled injector pen
Individual Dose
From 1 to 12 mg · precise dosingfrom 2,500 ₴
- ✓ Precise dosing tailored to you
- ✓ From 1 dose — try it
- ✓ Specialist support
Alluvi Retatrutide
40 mg · 4 doses · Pre-filled pen⚠️ Third-party manufacturer · not Eli Lilly · investigational
- ✓ 40 mg (4 doses of 10 mg)
- ✓ 1 injection per week
- ✓ Pre-filled pen — ready to use
Pen Peptide
12 mg · GoQuick pen⚠️ Third-party manufacturer · not Eli Lilly · investigational
- ✓ Dose: 12 mg
- ✓ 1 injection per week
- ✓ GoQuick — convenient format
* Prices are approximate. Contact a specialist for exact pricing and availability.
How the Retatrutide Dose is Gradually Increased
Starting with the minimum dose to adapt the body to the triple agonist. A DOZA specialist monitors the entire process.
| Dose | Weeks | Purpose |
|---|---|---|
| 2 mg | 1–4 | Adaptation |
| 4 mg | 5–8 | Initial |
| 8 mg | 9–12 | Working dose |
| 12 mg | 13+ | Maximum |
* Dosing is selected by a DOZA specialist after a free consultation
Retatrutide vs Mounjaro vs Ozempic
| Parameter | Retatrutide | Mounjaro | Ozempic |
|---|---|---|---|
| Active ingredient | Retatrutide | Tirzepatide | Semaglutide |
| Mechanism of action | ✅ GLP-1 + GIP + Glucagon | GLP-1 + GIP | GLP-1 only |
| Number of receptors | ✅ 3 (triple) | 2 (dual) | 1 (single) |
| Weight loss | ✅ -24.2% (Phase 2) | -22.5% (SURMOUNT-1) | -15% (STEP-1) |
| Manufacturer | Eli Lilly (molecule) / third-party manufacturers (product) | Eli Lilly | Novo Nordisk |
| Thermogenesis | ✅ ✅ Yes (glucagon) | ❌ No | ❌ No |
| Frequency | 1× per week | 1× per week | 1× per week |
Detailed comparison of Mounjaro and Ozempic — Mounjaro vs Ozempic: Full Comparison
Retatrutide Catalog
Retatrutide is available at DOZA with delivery across Ukraine. Cold chain 2–8°C, specialist consultation, program support.
📚 Sources
- • Retatrutide Phase 2 (NEJM, 2023) — Triple hormone receptor agonist for obesity, 338 participants, 48 weeks, -24.2% weight loss
- • SURMOUNT-1 (NEJM, 2022) — Tirzepatide for weight management, 2539 participants, 72 weeks, -22.5%
- • STEP-1 (NEJM, 2021) — Semaglutide 2.4 mg, 1961 participants, 68 weeks, -14.9%
- • Eli Lilly: Retatrutide Phase 3 TRIUMPH program initiated (2023)
Frequently Asked Questions about Retatrutide
Retatrutide is an innovative triple receptor agonist targeting GLP-1, GIP and glucagon. Unlike existing products (Ozempic — single receptor, Mounjaro — dual), Retatrutide activates three key weight regulation pathways simultaneously, providing triple action for weight control. Retatrutide is an investigational Phase 3 molecule (TRIUMPH program, Eli Lilly).
Анастасія Шаповал
Спеціаліст з метаболічних програм та контролю ваги
Take a free test
2 minIn 2 minutes, find out which program suits you best. Personalized weight loss and cost estimate.
See Also
Retatrutide Catalog
Retatrutide with delivery across Ukraine
Mounjaro
Dual GLP-1+GIP — up to -22.5% weight loss
Ozempic
GLP-1 agonist — up to -15% weight loss
Weight Loss with DOZA
All weight loss methods and programs
Retatrutide — Complete Guide 2026
Why the triple agonist is called 'heavy artillery'
Retatrutide vs Mounjaro — What to Choose
-24.2% vs -22.5%: detailed comparison for 2026
Retatrutide Side Effects
Difference from Mounjaro and Ozempic — what to expect
Retatrutide Dosing — 2.5 → 12 mg
How to start without setbacks: step-by-step guide